ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2166

Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization

Fu-Nien Tsai, Northwestern University, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Apoptosis, kinase, macrophages and toll-like receptors, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors

Session Type: Abstract Submissions (ACR)

Background/Purpose Only recently have monocytes and macrophages been accepted as critical players in the pathogenesis of SLE.  However, very little is known regarding the molecular rheostats that control the actions of monocytes and macrophages and their state of polarization.  Previous studies have shown that loss of Bim, a pro-apoptotic protein, in all cells leads to SLE-like disease and early mortality.  We have shown that reduction of Bim alters macrophage function independent of its role in apoptosis. Thus, we hypothesize that Bim is essential in monocytes and macrophages to limit the development of SLE-like disease. 

Methods We generated mice lacking Bim specifically in myeloid cells (CreLysMBimflox/flox) and assessed mice at 8, 16, 24, 36 and 48 weeks of age for characterization of SLE-like disease.  Macrophage turnover, activation, and polarization were examined in vivo and in vitrousing flow cytometric analyses and luminex based assays. 

Results CreLysMBimflox/flox mice displayed splenomegaly, lymphadenopathy, heightened amounts of serum pro-inflammatory cytokines, hypergammaglobulinemia, IC deposition in the kidney, proteinuria, GN, and early mortality as compared to Bimflox/flox and mice lacking Bim in either lymphocyte compartments.  Bim functions independently of its role in apoptosis in macrophages and monocytes, since macrophages from CreLysMBimflox/flox and from Bimflox/flox mice had equal BrdU uptake.  Moreover, MyD88 is not necessary as CreLysMBimflox/floxMyD88flox/flox mice also developed SLE-like disease.  The protein kinase Akt was increased in macrophages from CreLysMBimflox/flox mice and was co-immunoprecipatated with Bim in wild type cells.  Additionally, the BH3 domain, which is essential for its apoptotic function is necessary for suppressing inflammatory response in macrophages.  Mixed bone marrow chimeras were sufficient to reduce development of SLE-like disease in CreLysMBimflox/flox mice, which suggests that Bim may affect macrophage development or polarization.  To this end, we show that Bim is necessary to prevent the skewing of macrophages towards M2, pro-fibrotic phenotype. 

Conclusion The expression of Bim in monocytes and macrophages is sufficient to inhibit SLE-like pathogenesis.  These data suggest that Bim acts through its BH3 domain to reduce the intensity of inflammation and polarization status in macrophages through suppression the activity of Akt.  These studies are crucial for understanding the development and the persistence of SLE, as well as for translational studies leading to the development of new targets for SLE.


Disclosure:

F. N. Tsai,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bim-suppresses-the-development-of-glomerulonephritis-by-inhibiting-m2-polarization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology